Linked Life Data

7654394

Source:http://linkedlifedata.com/resource/pubmed/id/7654394

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1995-10-5
pubmed:abstractText
The clinical utility of intravenous contrast administration in nonneoplastic disease of the brain is well established. Although primarily providing improved diagnostic specificity, contrast use can also improve lesion detection. Applications are discussed in infection, vascular disorders, diseases of white matter, and trauma. On the basis of prospective studies, contrast use is advocated in all patient examinations in which there is a high clinical suspicion for intracranial disease. The role of high-dose contrast administration, with agents such as gadoteridol (Gd HP-DO3A), is just now being explored in nonneoplastic disease. Basic research suggests efficacy for high dose in disease states with partial or early blood-brain barrier disruption. Gadolinium chelates play as important a role in the evaluation of nonneoplastic disease of the brain as do iodinated agents in computed tomography. Contrast administration facilitates time-efficient and cost-effective diagnosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0899-3459
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
158-67
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
The use of MR contrast in nonneoplastic disease of the brain.
pubmed:affiliation
Department of Diagnostic Radiology, University of Kentucky, Lexington 40536-0098, USA.
pubmed:publicationType
Journal Article, Review